ArticleSouthern med review2011
Pharmaceutical policies in European countries in response to the global financial crisis.
Article in Southern med review, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Direct and indirect effects of economic sanctions on health: a systematic narrative literature review.BMC public health · 2024Pooled it
- The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review.Applied health economics and health policy · 2018Pooled it
- Pooled it
- Optimising Investment in Health Innovations in Europe.Journal of market access & health policy · 2026Article
- Pharmaceutical pricing and reimbursement information (PPRI): evolution and impact of a policy network over two decades.Journal of pharmaceutical policy and practice · 2026Review
- Analysis for health system resilience against the economic crisis: a best-fit framework synthesis.Health research policy and systems · 2025Article
- Disentangling prescribing behaviour of Cypriot physicians, within a complex framework of interacting.The International journal of health planning and management · 2022Article
- Policies and measures implemented to reduce the impact of international sanctions on Iran's pharmaceutical sector.Research in pharmaceutical sciences · 2022Article
- Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis.Health research policy and systems · 2021Article
- Formulation and Evaluation of Loperamide HCl Oro Dispersible Tablets.Pharmaceuticals (Basel, Switzerland) · 2020Article
- To evaluate the impact of opening up ownership of pharmacies in South Africa.Journal of pharmaceutical policy and practice · 2020Article
- Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.BMC health services research · 2019Article
- The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa.International journal of clinical pharmacy · 2019Article
- Article
- Social and economic value of Portuguese community pharmacies in health care.BMC health services research · 2017Article
- Cost analysis for the implementation of a medication review with follow-up service in Spain.International journal of clinical pharmacy · 2017Article
- Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.BMC health services research · 2017Article
- Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.Journal of market access & health policy · 2017Article
- Value added medicines: what value repurposed medicines might bring to society?Journal of market access & health policy · 2017Article
- Drug pricing and reimbursement information management: processes and decision making in the global economy.Journal of market access & health policy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this paper is to analyze which pharmaceutical policies European countries applied during the global financial crisis.
methodsWe undertook a survey with officials from public authorities for pharmaceutical pricing and reimbursement of 33 European countries represented in the PPRI (Pharmaceutical Pricing and Reimbursement Information) network based on a questionnaire. The survey was launched in September 2010 and repeated in February 2011 to obtain updated information.
resultsDuring the survey period from January 2010 to February 2011, 89 measures were identified in 23 of the 33 countries surveyed which were implemented to contain public medicines expenditure. Price reductions, changes in the co-payments, in the VAT rates on medicines and in the distribution margins were among the most common measures. More than a dozen countries reported measures under discussion or planned, for the remaining year 2011 and beyond. The largest number of measures were implemented in Iceland, the Baltic states (Estonia, Latvia, Lithuania), Greece, Spain and Portugal, which were hit by the crisis at different times.
conclusionsCost-containment has been an issue for high-income countries in Europe - no matter if hit by the crisis or not. In recent months, changes in pharmaceutical policies were reported from 23 European countries. Measures which can be implemented rather swiftly (e.g. price cuts, changes in co-payments and VAT rates on medicines) were among the most frequent measures. While the "crisis countries" (e.g. Baltic states, Greece, Spain) reacted with a bundle of measures, reforms in other countries (e.g. Poland, Germany) were not directly linked to the crisis, but also aimed at containing public spending. Since further reforms are under way, we recommend that the monitoring exercise is continued.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.